Latest From Neuronetics Inc.
The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
- Medical Devices
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Neuronetics Inc.
- Senior Management
Christopher Thatcher, Pres. & CEO
Peter Donato, CFO
Greg Harper, VP, Product Dev. & Operations
Cassie Hallberg, VP, Mktg.
Steve MacKinnon, VP, Sales
- Contact Info
Phone: (877) 600-7555
3222 Phoenixville Pike
Malvern, PA 19355
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.